SLS
NASDAQ · Biotechnology
Sellas Life Sciences Group I
$9.03
-0.11 (-1.20%)
Open$9.02
Previous Close$9.14
Day High$9.03
Day Low$9.01
52W High$15.88
52W Low$1.39
Volume—
Avg Volume8.87M
Market Cap1.93B
P/E Ratio—
EPS$-0.22
SectorBiotechnology
Analyst Ratings
Strong Buy
6 analysts
Price Target
+275.4% upside
Current
$9.03
$9.03
Target
$33.90
$33.90
$25.20
$33.90 avg
$43.49
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 353.66M | 369.01M | 305.89M |
| Net Income | 19.39M | 21.88M | 20.34M |
| Profit Margin | 5.5% | 5.9% | 6.7% |
| EBITDA | 24.66M | 25.78M | 21.04M |
| Free Cash Flow | 20.13M | 23.20M | 18.29M |
| Rev Growth | -7.4% | -1.2% | +17.7% |
| Debt/Equity | 0.38 | 0.40 | 0.41 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $288.24 | -2.24% | 81.4 | 513.86B |
| AMGN | Amgen Inc | $460.28 | -3.80% | 28.5 | 249.09B |
| GILD | Gilead Sciences Inc | $167.57 | -3.96% | — | 212.04B |
| VRTX | Vertex Pharmaceuticals Inc | $542.50 | -1.19% | 30.6 | 134.77B |
| REGN | Regeneron Pharmaceuticals | $902.90 | -2.98% | 19.5 | 84.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.66 | -2.74% | 28.8 | 23.28B |